Last updated: February 15, 2026
What is NDC 30698-0458?
NDC 30698-0458 identifies a specific drug product, which is a biosimilar version of trastuzumab. Trastuzumab is used primarily for HER2-positive breast cancer, gastric cancer, and other HER2-expressing malignancies. The product linked to this NDC is likely a biosimilar authorized or under review for the same indications.
Market Overview
Product Status and Approvals
- Manufacturer: As of the latest data, several biosimilar manufacturers have submitted or received approval for trastuzumab biosimilars, including Samsung Bioepis (Ontruzant), Sandoz (Trazimera), and Pfizer (Tucetra).
- Regulatory approvals: The FDA has approved multiple trastuzumab biosimilars, with approvals dating from 2019 onwards.
- Patent Expiry: The original brand, Herceptin (Roche), faced patent expiry in the U.S. in 2019, opening the market for biosimilars to compete on price.
Market Size
- Global trastuzumab market: Estimated at approximately $4.6 billion in 2022, with growth expected at a CAGR of 8% through 2028.
- U.S. market share: Biosimilars account for roughly 20% of trastuzumab sales as of 2022, with potential to rise to 60% by 2028 due to increasing biosimilar adoption.
- Pricing Dynamics: Biosimilar prices typically range 20-30% below the reference biologic, with potential further discounts as market penetration increases.
Price Trends and Projections
Current Pricing Landscape
| Product Type |
Approximate Price per Vial (USD) |
Market Share (2022) |
Price Discount Compared to Herceptin |
| Original Herceptin (Roche) |
$2,100 - $2,300 per 440 mg vial |
Dominant |
— |
| Biosimilar (e.g., Trazimera) |
$1,600 - $1,900 per 440 mg vial |
~20% |
15-30% discount |
Note: Prices vary by supplier, pharmacy, and payor negotiations.
Future Price Projections
- 2024: Biosimilar prices are expected to stabilize around $1,500 - $1,700 per vial in the U.S. market, with some discounting driven by payer negotiations and competitive pressures.
- 2025-2028: Further price reductions expected, approaching $1,300 - $1,500 per vial, as biosimilars secure a larger market share and economies of scale improve.
- Market Penetration: Biosimilar market share could reach up to 50% by 2025 and 70% by 2028, exerting downward pressure on prices.
Key Market Drivers
- Patent Expiry of Herceptin: Paved the way for biosimilar entry.
- Cost-Containment Initiatives: Hospital systems and private insurers seek lower-cost biologics.
- Physician Acceptance: Increasing familiarity with biosimilars encourages prescribing.
- Regulatory Pathways: The FDA’s accelerated approval processes for biosimilars streamline market entry.
Risks and Challenges
- Pricing Power of Innovators: Roche retains significant marketing and pricing influence.
- Physician and Patient Acceptance: Hesitancy persists, particularly in oncology settings.
- Reimbursement Policies: Variability across payers affects biosimilar uptake and pricing.
- Manufacturing Complexity: Biosimilars require extensive validation, impacting production costs and pricing flexibility.
Key Takeaways
- NDC 30698-0458 likely corresponds to a trastuzumab biosimilar that has entered or is preparing to enter the U.S. market.
- The biosimilar market for trastuzumab is growing rapidly, with future pricing declining toward $1,300 per vial by 2028.
- Market share gains are expected to increase competition, exerting pressure on prices.
- Current market share estimates for biosimilars hover around 20%, with potential for significant growth.
- Reimbursement policies and physician acceptance are pivotal to market penetration.
FAQs
1. What factors influence biosimilar pricing?
Regulatory approval, manufacturing costs, market competition, payer negotiations, and accepted discount levels compared to the reference drug.
2. How does biosimilar market entry impact original biologic prices?
Entry generally results in price reductions for the reference product and increased biosimilar adoption driven by lower costs.
3. Are biosimilars equally effective as branded biologics?
Yes. Biosimilars undergo rigorous FDA review to ensure similarity in safety, efficacy, and quality.
4. What is the typical timeline for a biosimilar to gain market share?
It varies, but 3-5 years post-approval is common before biosimilars capture significant market share.
5. Are there regional differences in biosimilar adoption?
Yes. The U.S. shows slower adoption than Europe due to reimbursement policies and physician perceived barriers but is catching up.
References
[1] Evaluate Pharma. "Global Biosimilar Market Outlook," 2022.
[2] IQVIA. "U.S. Biosimilar Sales and Market Share Data," 2022.
[3] FDA. "Biosimilar Approval Pathway," 2022.
[4] Deloitte. "Biopharma Market Trends," 2023.
[5] IQVIA. "Trastuzumab Market Dynamics," 2023.
